Divi Cornec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6778709/publications.pdf

Version: 2024-02-01

117453 149479 56 3,718 122 34 h-index citations g-index papers 136 136 136 4192 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients. Nature Reviews Rheumatology, 2016, 12, 570-579.	3.5	219
2	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis and Rheumatology, 2019, 71, 2100-2111.	2.9	202
3	Contribution of salivary gland ultrasonography to the diagnosis of Sjögren's syndrome: Toward new diagnostic criteria?. Arthritis and Rheumatism, 2013, 65, 216-225.	6.7	188
4	Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: A systematic review. Autoimmunity Reviews, 2013, 12, 416-420.	2.5	146
5	B cells in Sjögren's syndrome: From pathophysiology to diagnosis and treatment. Journal of Autoimmunity, 2012, 39, 161-167.	3.0	145
6	The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota. Arthritis and Rheumatology, 2017, 69, 2338-2350.	2.9	126
7	Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Annals of the Rheumatic Diseases, 2016, 75, 1506-1510.	0.5	124
8	Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells. Journal of Autoimmunity, 2013, 41, 175-181.	3.0	108
9	Prevalence of Primary Sjögren's Syndrome in a US Populationâ€Based Cohort. Arthritis Care and Research, 2017, 69, 1612-1616.	1.5	102
10	Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open, 2016, 2, e000179.	1.8	88
11	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. RMD Open, 2017, 3, e000364.	1.8	87
12	Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 1623-1628.	2.9	85
13	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	2.9	81
14	Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study. Mayo Clinic Proceedings, 2018, 93, 597-606.	1.4	69
15	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. Journal of Autoimmunity, 2016, 67, 102-110.	3.0	68
16	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. Nature Communications, 2021, 12, 3523.	5.8	67
17	Severe Healthâ€Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patientâ€Reported Outcomes: Data From a Large Therapeutic Trial. Arthritis Care and Research, 2017, 69, 528-535.	1.5	65
18	Sjögren's syndrome: Where do we stand, and where shall we go?. Journal of Autoimmunity, 2014, 51, 109-114.	3.0	61

#	Article	IF	Citations
19	Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary SjĶgren's syndrome. Joint Bone Spine, 2016, 83, 681-685.	0.8	58
20	The Fmsâ€like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 2010, 62, 3447-3456.	6.7	55
21	Antiâ€B lymphocyte immunotherapy is associated with improvement of periodontal status in subjects with rheumatoid arthritis. Journal of Clinical Periodontology, 2015, 42, 817-823.	2.3	52
22	ANCA-associated vasculitis in patients with primary Sj \tilde{A} ¶gren's syndrome: Detailed analysis of 7 new cases and systematic literature review. Autoimmunity Reviews, 2015, 14, 742-750.	2.5	52
23	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology, 2015, 54, 1699-1708.	0.9	49
24	The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 278-287.	2.9	49
25	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	2.9	49
26	Is primary Sjögren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe: TableÂ1. Annals of the Rheumatic Diseases, 2015, 74, e25-e25.	0.5	47
27	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.4	46
28	High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary SjÁ¶gren's Syndrome: Data from the TEARS Randomized Trial. PLoS ONE, 2016, 11, e0162787.	1.1	43
29	Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome. Mayo Clinic Proceedings, 2017, 92, 734-743.	1.4	42
30	TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. Journal of Autoimmunity, 2011, 37, 190-197.	3.0	40
31	Measures to improve microbial quality surveillance of gastrointestinal endoscopes. Endoscopy, 2016, 48, 704-710.	1.0	40
32	Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. Journal of Autoimmunity, 2017, 84, 122-131.	3.0	40
33	Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine, 2017, 84, 595-598.	0.8	37
34	Diagnostic Accuracy of ACR/EULAR 2010 Criteria for Rheumatoid Arthritis in a 2-Year Cohort. Journal of Rheumatology, 2011, 38, 1250-1257.	1.0	35
35	Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren's syndrome. Arthritis Research and Therapy, 2014, 16, R15.	1.6	33
36	Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sjögren's syndrome?. Joint Bone Spine, 2016, 83, 301-306.	0.8	33

#	Article	IF	Citations
37	A prospective evaluation of dental and periodontal status in patients with suspected Sjögren's syndrome. Joint Bone Spine, 2016, 83, 235-236.	0.8	33
38	Memory B Cells and Response to Abatacept in Rheumatoid Arthritis. Clinical Reviews in Allergy and Immunology, 2017, 53, 166-176.	2.9	33
39	Lung involvement in ANCA-associated vasculitis. Presse Medicale, 2020, 49, 104039.	0.8	33
40	Innate B Cells: the Archetype of Protective Immune Cells. Clinical Reviews in Allergy and Immunology, 2020, 58, 92-106.	2.9	30
41	Time-course of ultrasound abnormalities of major salivary glands in suspected Sjögren's syndrome. Joint Bone Spine, 2018, 85, 227-232.	0.8	29
42	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.5	27
43	Salivary gland ultrasound to diagnose Sjogren's syndrome: a claim to standardize the procedure. Rheumatology, 2015, 54, 199-200.	0.9	26
44	The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmunity Reviews, 2020, 19, 102670.	2.5	26
45	Eosinophilic Granulomatosis With Polyangiitis. Chest, 2020, 157, 1086-1099.	0.4	26
46	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	3.2	24
47	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Autoimmunity, 2019, 105, 102302.	3.0	24
48	A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1550-1561.	2.9	24
49	Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. Clinical Reviews in Allergy and Immunology, 2017, 53, 14-27.	2.9	22
50	Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis. Joint Bone Spine, 2012, 79, 581-585.	0.8	21
51	Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. Seminars in Arthritis and Rheumatism, 2018, 48, 77-82.	1.6	21
52	Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Annals of Hematology, 2012, 91, 715-721.	0.8	20
53	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	0.9	20
54	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. Scientific Reports, 2020, 10, 11567.	1.6	20

#	Article	IF	Citations
55	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. PLoS ONE, 2015, 10, e0133907.	1.1	19
56	Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?. Annals of the Rheumatic Diseases, 2016, 75, e33-e33.	0.5	19
57	Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease. Expert Review of Clinical Immunology, 2020, 16, 51-61.	1.3	19
58	The future of B cell-targeted therapies in Sjögren's syndrome. Immunotherapy, 2013, 5, 639-646.	1.0	18
59	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respiratory Medicine, 2018, 142, 66-72.	1.3	18
60	Localized Myofascial Inflammation Revealed by Magnetic Resonance Imaging in Recent-onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy. Journal of Rheumatology, 2019, 46, 1619-1626.	1.0	17
61	Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. Scientific Reports, 2021, 11, 23292.	1.6	16
62	Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?. Clinical Reviews in Allergy and Immunology, 2017, 53, 277-290.	2.9	15
63	Classification criteria versus physician's opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine, 2018, 85, 85-91.	0.8	14
64	Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort. RMD Open, 2015, 1, e000070.	1.8	14
65	Association of Smoking and Obesity on the Risk of Developing Primary Sjögren Syndrome: A Population-based Cohort Study. Journal of Rheumatology, 2019, 46, 727-730.	1.0	13
66	Lymphoma complicating rheumatoid arthritis: results from a French case–control study. RMD Open, 2021, 7, e001698.	1.8	13
67	Association of mastocytosis with inflammatory joint diseases: A series of 31 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 362-365.	1.6	12
68	Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrology Dialysis Transplantation, 2017, 32, gfw384.	0.4	12
69	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clinical Pharmacokinetics, 2020, 59, 519-530.	1.6	12
70	Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). Joint Bone Spine, 2021, 88, 105162.	0.8	12
71	Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert Review of Anticancer Therapy, 2018, 18, 981-989.	1.1	11
72	Assessment of major salivary gland size in primary Sjögren's syndrome: Comparison between clinical examination and ultrasonography. Joint Bone Spine, 2019, 86, 627-632.	0.8	9

#	Article	IF	CITATIONS
73	Expression Quantitative Trait Locus Analysis in Systemic Sclerosis Identifies New Candidate Genes Associated With Multiple Aspects of Disease Pathology. Arthritis and Rheumatology, 2021, 73, 1288-1300.	2.9	9
74	Could abatacept directly target expanded plasmablasts in IgG4-related disease?. Annals of the Rheumatic Diseases, 2016, 75, e73-e73.	0.5	8
75	New onset of rheumatoid vasculitis during abatacept therapy and subsequent improvement after rituximab. Joint Bone Spine, 2016, 83, 605-606.	0.8	8
76	Temporal Artery Ultrasound to Diagnose Giant Cell Arteritis: A Practical Guide. Ultrasound in Medicine and Biology, 2021, 47, 201-213.	0.7	8
77	Molecular Mechanisms Driving IL-10- Producing B Cells Functions: STAT3 and c-MAF as Underestimated Central Key Regulators?. Frontiers in Immunology, 2022, 13, 818814.	2.2	8
78	New biological therapies in Sjögren's syndrome. Best Practice and Research in Clinical Rheumatology, 2015, 29, 783-793.	1.4	7
79	Hospitalisation rates among patients with primary Sjögren's syndrome: a population-based study, 1995–2016. RMD Open, 2018, 4, e000575.	1.8	7
80	Abatacept Promotes Regulatory B Cell Functions, Enhancing Their Ability to Reduce the Th1 Response in Rheumatoid Arthritis Patients through the Production of IL-10 and TGF-Î ² . Journal of Immunology, 2021, 207, 470-482.	0.4	7
81	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	2.3	7
82	Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Seminars in Arthritis and Rheumatism, 2020, 50, 1109-1113.	1.6	6
83	Aortic involvement in giant cell arteritis. Joint Bone Spine, 2021, 88, 105045.	0.8	6
84	Lymphopenia in early arthritis: Impact on diagnosis and 3-year outcomes (ESPOIR cohort). Joint Bone Spine, 2015, 82, 417-422.	0.8	5
85	Current and Future Treatment Options for Eosinophilic Granulomatosis With Polyangiitis. Current Treatment Options in Rheumatology, 2017, 3, 193-206.	0.6	5
86	Peripheral-blood b-cell subset disturbances in inflammatory joint diseases induced by Tropheryma whipplei. PLoS ONE, 2019, 14, e0211536.	1.1	5
87	Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?. Annals of the Rheumatic Diseases, 2020, 79, e160-e160.	0.5	5
88	Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine, 2021, 88, 105117.	0.8	5
89	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. Clinical Pharmacokinetics, 2022, 61, 423-437.	1.6	5
90	Diagnostic impact of routine Lyme serology in recent-onset arthritis: results from the ESPOIR cohort. RMD Open, 2016, 2, e000120.	1.8	4

#	Article	IF	CITATIONS
91	Salivary Glands and Periodontal Changes in a Population of SjĶgren's and Sicca Syndrome Treated by Pilocarpine: A Pilot Study. Rheumatology and Therapy, 2021, 8, 219-231.	1.1	4
92	Comparison of halo and compression signs assessed by a high frequency ultrasound probe for the diagnosis of Giant Cell Arteritis. Journal of Ultrasound, 2022, 25, 837-845.	0.7	4
93	Which autoantibodies announce that lupus nephritis is on the way?. International Journal of Clinical Rheumatology, 2009, 4, 287-295.	0.3	3
94	Intérêt de la triple association méthotrexate, salazopyrine et hydroxychloroquine dans la polyarthrite rhumatoìde : analyse systématique de la littérature. Revue Du Rhumatisme (Edition) Tj ETQq0 (OngBT/C	værlock 10 ⁻
95	Current diagnostic tools for Sjögren's syndrome. International Journal of Clinical Rheumatology, 2013, 8, 281-290.	0.3	3
96	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2019, 46, 1243-1243.	1.0	3
97	Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. Arthritis and Rheumatology, 2021, 73, 717-718.	2.9	3
98	Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases. Frontiers in Oncology, 2021, 11, 644282.	1.3	3
99	The diversity of the plasmablast signature across species and experimental conditions: A metaâ€analysis. Immunology, 2021, 164, 120-134.	2.0	3
100	Valeur discriminante des items des crità res ACR/EULAR 2010 : analyse systà © matique de la littà © rature. Revue Du Rhumatisme (Edition Francaise), 2011, 78, S3-S10.	0.0	2
101	Evolution of early arthritis to spondyloarthritis after a 10-year follow-up. Joint Bone Spine, 2013, 80, 345-347.	0.8	2
102	From BLISS to ILLUMINATE studies: "Blys repetita placentâ€?: TableÂ1. Annals of the Rheumatic Diseases, 2016, 75, e10-e10.	0.5	2
103	Anti-neutrophil cytoplasmic antibody-associated chronic inflammatory arthritis without vasculitis. Data from a French nationwide survey. Autoimmunity Reviews, 2018, 17, 1268-1269.	2.5	2
104	Comparison of 18―and 22â€MHz probes for the ultrasonographic diagnosis of giant cell arteritis. Journal of Clinical Ultrasound, 2021, 49, 546-553.	0.4	2
105	Impact of the COVID-19 pandemic on therapeutic management of rheumatoid arthritis in Brittany (France). Joint Bone Spine, 2021, 88, 105179.	0.8	2
106	Définition et traitement d'une polyarthrite rhumatoÃ⁻de sévère d'emblée en 2010 : analyse systà de la littérature. Revue Du Rhumatisme (Edition Francaise), 2011, 78, S11-S18.	©matique	1
107	Reply. Arthritis and Rheumatism, 2013, 65, 1951-1951.	6.7	1
108	Histological and imaging characteristics of acute colchicine myotoxicity. Joint Bone Spine, 2022, 89, 105341.	0.8	1

#	Article	IF	CITATIONS
109	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. Joint Bone Spine, 2022, 89, 105390.	0.8	1
110	Place de l'échographie ostéo-articulaire dans la prise en charge de la pseudopolyarthrite rhizomélique. Revue Du Rhumatisme Monographies, 2015, 82, 202-207.	0.0	0
111	La lymphopénie dans la polyarthrite débutanteÂ: impact sur le diagnostic et les résultats à 3ans (la) Tj ETÇ	0q1.1 0.78	4314 rgBT
112	Reply. Arthritis Care and Research, 2018, 70, 953-954.	1.5	0
113	Efficacité et tolérance du fébuxostat chez 73Âpatients goutteux avec une insuffisance rénale chronique stade 4/5Â: étude rétrospective de 10Âcentres. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 370-374.	0.0	0
114	Évolution des anomalies observées à l'échographie des glandes salivaires principales dans les cas de suspicion de syndrome de Gougerot-Sjögren. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 465-470.	0.0	0
115	Prise en charge pratique des patients sous inhibiteurs de Janus Kinases (JAKi). Fiches pratiques élaborées par le Club Rhumatismes et Inflammation (CRI), Association reconnue par la Société Française de Rhumatologie (SFR). Revue Du Rhumatisme (Edition Francaise), 2018, 85, 1-108.	0.0	O
116	Manifestations ostéo-articulaires secondaires à une piqûre, griffure, morsure ou à germes inhabituels ou émergents. Revue Du Rhumatisme Monographies, 2018, 85, 274-280.	0.0	0
117	Reply. Arthritis and Rheumatology, 2020, 72, 506-508.	2.9	0
118	Artérite gigantocellulaireÂ: expression cervico-céphalique. Revue Du Rhumatisme Monographies, 2021, 88, 309-316.	0.0	0
119	Predictors of Early Response to Single Agent Rituximab in Patients with Indolent Lymphoma Blood, 2009, 114, 1946-1946.	0.6	O
120	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open, 2021, 7, .	1.8	0
121	Dr. Berti et al reply. Journal of Rheumatology, 2022, 49, 234.2-234.	1.0	O
122	Immune Cell Signatures to Stratify Patients With Systemic Autoimmune Diseases: A Step Toward Individualized Medicine?. Arthritis and Rheumatology, 2022, 74, 1727-1729.	2.9	0